Simultaneous Catabolite Identification and Quantitation of Large Therapeutic Protein at the Intact Level by Immunoaffinity Capture Liquid Chromatography–High-Resolution Mass Spectrometry

• Published in: Analytical chemistry (Washington) 2017-06, Vol.89 (11), p.6065-6075
• Main Authors: Kang, Lijuan, Camacho, Raul C, Li, Wenyu, D’Aquino, Katharine, You, Seohee, Chuo, Vanessa, Weng, Naidong, Jian, Wenying
• Format: Article
• Language: English
• Subjects: Biological properties; Biological samples; Biotransformation; Catabolism; Catabolites; Chemistry; Chromatography; Computer programs; Digestion; Diseases; Drug discovery; Fc receptors; Fusion protein; Glucagon; Glucagon-like peptide 1; High resolution; In vivo methods and tests; Integrity; Levels; Liquid chromatography; Mass spectrometry; Mass spectroscopy; Mice; Peptides; Pharmacodynamics; Pharmacokinetics; Pharmacology; Proteins; Proteolysis; Quantitation; Software; Trypsin; Water analysis
• ISSN: 0003-2700; 1520-6882
• DOI: 10.1021/acs.analchem.7b00674

As therapeutic recombinant fusion proteins become more widely applicable for the treatment of various types of diseases, there is an increased demand for universal methods such as liquid chromatography (LC)–mass spectrometry (MS) for the determination of their pharmacokinetic properties, particularly their catabolism. The most common approach of analyzing proteins by LC–MS is to digest them into peptides, which can serve as surrogates of the protein. Alternatively, we have developed a novel high-resolution mass spectrometry (HRMS) based approach for analyzing large-molecule proteins at the intact level in biological samples without digestion. We established an immunoaffinity capture LC–HRMS method to quantify the intact parent molecule while simultaneously identifying catabolites for recombinant fusion proteins. We describe this method using dulaglutide, a glucagon-like peptide 1 (GLP1)–Fc fusion protein. Two proteolytic sites within the GLP1 peptide sequence of dulaglutide were identified using this novel LC–HRMS analysis in vivo in mice. These proteolytic sites were identified with the intact molecule being quantified simultaneously. Together with the trypsin digestion based LC–MS/MS analysis using surrogate peptides from different domains of the analyte, an insightful understanding of the pharmacokinetics and in vivo biotransformation of dulaglutide was obtained. Thus, this method enables simultaneous acquisition of both intact drug concentration and important catabolite information for this recombinant fusion protein, providing valuable insight into the integrity of the molecule and its catabolism in vivo. This is critical for designing and screening novel protein therapeutics and for understanding their pharmacokinetics and pharmacodynamics. With continuing advancement of LC–HRMS and software, this method can be very beneficial in drug discovery and development.